All In Biotech

Drug Trial Radar · NCT06977841

Tegoprazan-Based Therapies for H. Pylori Eradication: A Randomized Controlled Trial

Efficacy and Safety of Tegoprazan-Based Dual, Triple, and Quadruple Therapies as First-Line Regimens for Helicobacter Pylori Eradication: A Prospective Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: May 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 640 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

640

Actual

Start

Jun 10, 2025

Primary completion

Mar 10, 2026

Study completion Mar 10, 2026

Sponsor

Lead sponsor
Zhongshan Hospital (Xiamen), Fudan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Current first-line Helicobacter pylori eradication protocols involve multidrug regimens comprising a proton pump inhibitor (PPI) or bismuth agent combined with dual antibiotics (e.g., clarithromycin, amoxicillin, quinolones, furazolidone, nitroimidazoles, or tetracycline) administered for 7-14 days. In China, the bismuth-containing quadruple therapy (BQT) remains the standard first-line treatment for H. pylori infection. However, BQT implementation is challenged by polypharmacy burdens, substantial adverse events, and suboptimal treatment adherence. Emerging evidence suggests that simplified dual therapies pairing acid suppressants (PPIs or potassium-competitive acid blockers \[P-CABs\]) with high-dose amoxicillin achieve comparable eradication rates to BQT while demonstrating superior tolerability and adherence profiles. Notably, the comparative efficacy of tetracycline-based versus amoxicillin-based dual regimens remains unexamined in controlled clinical trials. Our preliminary investigations established that optimized PPI-amoxicillin dual therapy achieves \>90% eradication rates in treatment-naïve populations. Building on these findings, this prospective randomized controlled trial will comparatively assess the effectiveness of tegoprazan-a novel P-CAB exhibiting potent acid inhibition-when co-administered with either amoxicillin or tetracycline in H. pylori-positive adults. The investigation aims to establish an evidence framework for streamlining eradication protocols through pharmacodynamic optimization while mitigating antimicrobial resistance development.

Conditions

  • Helicobacter Pylori Eradication
  • Adverse Reaction

Interventions

  • TegoprazanDrug

    50 mg twice daily (BID), d1-14.

  • AmoxicillinDrug

    In the Tegoprazan-Amoxicillin Dual Therapy group, amoxicillin 750 mg four times daily (QID) on days 1-14; in the Tegoprazan-Amoxicillin-Tetracycline Triple Therapy group and the Tegoprazan-Amoxicillin-Tetracycline-Bismuth Quadruple Therapy group, amoxicillin 1000 mg twice daily.

  • TetracyclineDrug

    In the Tegoprazan-Tetracycline Dual Therapy group, tetracycline tablets 500 mg (Hainan Pharmaceutical Factory Co., Ltd. No. 1 Pharmaceutical Factory) were administered four times daily; in the Tegoprazan-Amoxicillin-Tetracycline Triple Therapy and Tegoprazan-Amoxicillin-Tetracycline-Bismuth Quadruple Therapy groups, tetracycline tablets 500 mg were administered three times daily.

  • BismuthDrug

    In the Tegoprazan-Amoxicillin-Tetracycline-Bismuth Quadruple Therapy group, bismuth potassium citrate capsules 240 mg (Hunan Warner Pharmaceutical Co., Ltd.) were administered twice daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. H. pylori eradication rateTime frame: 44 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhongshan Hospital (Xiamen), Fudan University

    Xiamen, Fujian, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.